
    
      This is a single arm, open-label Phase 2 study designed to evaluate the effect of maintenance
      olaparib treatment after response to platinum-based chemotherapy in patients with BRCA wild
      type platinum sensitive recurrent ovarian cancer. The goal is to identify a clinical and
      molecular profile able to select a group of patients, treated with olaparib as maintenance,
      with a favorable prognosis.
    
  